Assembly Biosciences Inc. is set to raise approximately $100 million to advance its clinical pipeline for viral and liver diseases, a move that extends its research runway at the cost of diluting existing shareholders. The biotech company, which develops therapies for hepatitis B and delta viruses, priced the offering at $26.50 per share.
The company plans to use the net proceeds to fund the clinical development of its pipeline candidates and for general corporate purposes, according to a statement released on May 22. The financing is critical for development-stage biotechnology firms like Assembly Bio, which require significant capital to fund costly and lengthy clinical trials before generating revenue.
The underwritten offering consists of 3,358,602 shares of common stock at $26.50 per share and pre-funded warrants to purchase up to 415,000 shares of common stock at $26.499 per warrant. The offering price for the common stock represents a slight discount to its last closing price of $26.48. Underwriters have a 30-day option to purchase up to an additional 566,040 shares.
This capital raise shores up Assembly Bio’s balance sheet to continue its work on therapeutics for herpesvirus, hepatitis delta virus (HDV), and hepatitis B virus (HBV). The participation of major healthcare investors, including partner Gilead Sciences, Inc., alongside firms like Farallon Capital Management and Commodore Capital, suggests strong investor conviction in the company’s scientific platform and its potential to address significant unmet medical needs.
Market Reaction and Analyst Outlook
For investors, the offering presents a classic biotech trade-off: immediate share dilution versus a strengthened financial position that enables long-term value creation. The issuance of nearly 3.8 million new shares (including warrants) will increase the total number of shares outstanding.
Despite the dilution, analyst outlook remains positive, reflecting confidence in the company's pipeline. Before the announcement, the median analyst price target for Assembly Biosciences stood at $46.50. Recent targets include a $50.00 price objective from H.C. Wainwright & Co. and $43.00 from Guggenheim, one of the book-running managers for the offering alongside UBS Investment Bank and Mizuho. The offering is expected to close on or about May 26, 2026.
This article is for informational purposes only and does not constitute investment advice.
